Market revenue in 2021 | USD 2.2 million |
Market revenue in 2030 | USD 4.1 million |
Growth rate | 7.2% (CAGR from 2021 to 2030) |
Largest segment | Biomarker assay development & validation |
Fastest growing segment | Flow cytometry |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biomarker Assay Development & Validation, Flow cytometry, Others( Biomarker immunoassays, Biomarker Assessment) |
Key market players worldwide | Eurofins Scientific SE, SGS AG, Charles River Laboratories International Inc, Labcorp Drug Development, Thermo Fisher Scientific Inc, Icon PLC, IQVIA Holdings Inc, Syneos Health, Intertek Group PLC, BioAgilytix Labs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker testing services market will help companies and investors design strategic landscapes.
Biomarker assay development & validation was the largest segment with a revenue share of 59.09% in 2024. Horizon Databook has segmented the Malaysia biomarker testing services market based on biomarker assay development & validation, flow cytometry, others( biomarker immunoassays, biomarker assessment) covering the revenue growth of each sub-segment from 2018 to 2030.
The government and private sector investments in R&D are expected to stimulate the demand for biomarker testing services. The increasing funding for R&D projects is expected to improve the demand for biomarker testing services.
The country has been trying to strengthen its pharmaceutical industry, which is expected to increase demand for these services. These services are essential for ensuring pharmaceutical products' safety, efficacy, and quality.
For instance, in August 2023, the first central oncology laboratory dedicated to clinical trials was inaugurated in Malaysia. The Minister of Health (MOH) officially inaugurated Hematogenix, Malaysia's pioneering central oncology laboratory dedicated to clinical trials.
Horizon Databook provides a detailed overview of country-level data and insights on the Malaysia biomarker testing services market , including forecasts for subscribers. This country databook contains high-level insights into Malaysia biomarker testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account